Literature DB >> 33223469

Regulation and characterization of tumor-infiltrating immune cells in breast cancer.

Qile Dai1, Weimiao Wu1, Amei Amei2, Xiting Yan3, Lingeng Lu4, Zuoheng Wang5.   

Abstract

The effect of immunosuppression blockade therapies depends on the infiltration of effector T cells and other immune cells in tumor. However, it is unclear how molecular pathways regulate the infiltration of immune cells, as well as how interactions between tumor-infiltrating immune cells and T cell activation affect breast cancer patient survival. CIBERSORT was used to estimate the relative abundance of 22 immune cell types. The association between mRNAs and immune cell abundance were assessed by Spearman correlation analysis. Enriched pathways were identified using MetaCore pathway analysis. The interactions between the T cell activation status and the abundance of tumor-infiltrating immune cells were evaluated using Kaplan-Meier survival and multivariate Cox regression models in a publicly available dataset of 1081 breast cancer patients. The role of tumor-infiltrating B cells in antitumor immunity, immune response of T cell subsets, and breakdown of CD4+ T cell peripheral tolerance were positively associated with M1 macrophage and CD8+ T cell but negatively associated with M2 macrophage. Abundant plasma cell was associated with prolonged survival (HR = 0.46, 95% CI: 0.32-0.67), and abundant M2 macrophage was associated with shortened survival (HR = 1.78, 95% CI: 1.23-2.60). There exists a significant interaction between the T cell activation status and the resting DC abundance level (p = 0.025). Molecular pathways associated with tumor-infiltrating immune cells provide future directions for developing cancer immunotherapies to control immune cell infiltration, and further influence T cell activation and patient survival in breast cancer.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Cancer survival; Molecular pathway; T cell activation score; Tumor-infiltrating immune cell

Mesh:

Year:  2020        PMID: 33223469      PMCID: PMC7855363          DOI: 10.1016/j.intimp.2020.107167

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  42 in total

Review 1.  Antigen presentation and T cell stimulation by dendritic cells.

Authors:  Pierre Guermonprez; Jenny Valladeau; Laurence Zitvogel; Clotilde Théry; Sebastian Amigorena
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

Review 2.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

3.  Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance.

Authors:  Hans Christian Probst; Jacques Lagnel; George Kollias; Maries van den Broek
Journal:  Immunity       Date:  2003-05       Impact factor: 31.745

4.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

Authors:  Rico D Bense; Christos Sotiriou; Martine J Piccart-Gebhart; John B A G Haanen; Marcel A T M van Vugt; Elisabeth G E de Vries; Carolien P Schröder; Rudolf S N Fehrmann
Journal:  J Natl Cancer Inst       Date:  2016-10-13       Impact factor: 13.506

5.  Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome.

Authors:  Michael J Campbell; Nathan Y Tonlaar; Elisabeth R Garwood; Dezheng Huo; Dan H Moore; Andrey I Khramtsov; Afred Au; Frederick Baehner; Yinghua Chen; David O Malaka; Amy Lin; Oyinlolu O Adeyanju; Shihong Li; Can Gong; Michael McGrath; Olufunmilayo I Olopade; Laura J Esserman
Journal:  Breast Cancer Res Treat       Date:  2010-09-15       Impact factor: 4.872

6.  The prognostic landscape of genes and infiltrating immune cells across human cancers.

Authors:  Andrew J Gentles; Aaron M Newman; Chih Long Liu; Scott V Bratman; Weiguo Feng; Dongkyoon Kim; Viswam S Nair; Yue Xu; Amanda Khuong; Chuong D Hoang; Maximilian Diehn; Robert B West; Sylvia K Plevritis; Ash A Alizadeh
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

7.  The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer.

Authors:  Miriam Lohr; Karolina Edlund; Johan Botling; Seddik Hammad; Birte Hellwig; Amnah Othman; Anders Berglund; Mats Lambe; Lars Holmberg; Simon Ekman; Michael Bergqvist; Fredrik Pontén; Cristina Cadenas; Rosemarie Marchan; Jan G Hengstler; Jörg Rahnenführer; Patrick Micke
Journal:  Cancer Lett       Date:  2013-01-28       Impact factor: 8.679

8.  Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.

Authors:  David R Kroeger; Katy Milne; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2016-01-13       Impact factor: 12.531

9.  Dendritic cell density and activation status in human breast cancer -- CD1a, CMRF-44, CMRF-56 and CD-83 expression.

Authors:  B J Coventry; P-L Lee; D Gibbs; D N J Hart
Journal:  Br J Cancer       Date:  2002-02-12       Impact factor: 7.640

10.  The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens.

Authors:  Gabrielle T Belz; Georg M N Behrens; Chris M Smith; Jacques F A P Miller; Claerwen Jones; Kristina Lejon; C Garrison Fathman; Scott N Mueller; Ken Shortman; Francis R Carbone; William R Heath
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  2 in total

1.  RecQ mediated genome instability 2 (RMI2): a potential prognostic and immunological biomarker for pan-cancers.

Authors:  Wei Wei; Xiaomei Ying; Liang Chen; Qingmei Sun; Xiaohuan Lu; Yang Xia; Rubin Xu; Zhechen Zhu; Dong Zhang; Qikai Tang; Li Li; Jiaheng Xie; Hongzhu Yu
Journal:  Aging (Albany NY)       Date:  2022-05-12       Impact factor: 5.955

Review 2.  Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?

Authors:  Liqin Yao; Gang Jia; Lingeng Lu; Wenxue Ma
Journal:  Curr Oncol       Date:  2022-07-12       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.